One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected ...

PCRX-201 became part of Pacira's portfolio in 2021, but was originally developed at Baylor and then by GQ Bio Therapeutics, ...

Researchers have discovered a novel approach to protecting insulin-producing beta cells from the damaging effects of glucolipotoxicity - a harmful condition linked to the progression of type 2 ...

and four to 12 days for adenoviral conjunctivitis. The government data doesn't specify which kind of adenovirus is currently spiking, however. And there are also several ways it can spread ...

Data from the Phase II trial saw three of the seven patients dosed with CAN-2409 surviving for more than 35 months.

and four to 12 days for adenoviral conjunctivitis. Despite a surge in cases, government data hasn't pinpointed which specific adenovirus type is responsible. Transmission of the virus occurs ...

Following injury, many organs are capable of rapid regeneration of necrotic tissue to regain normal function. In contrast, ...

Ferring Pharma’s Adstiladrin is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated in a multi-centre clinical study of ...